Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00750 (
PLA
)
16,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Blends of cross-linked poly(ethylene glycol) dimethacrylate (PEGDMA) and poly(d,l-lactide) (
PLA
) were prepared by mixing photoactive PEGDMA (molecular mass: 875 g/mol) and
PLA
, and subsequently photopolymerizing the mixture with visible light. The effects of
PLA
molecular mass and mass fraction on the rheological properties of the PEGDMA/
PLA
mixtures, and on the degree of methacrylate vinyl conversion (DC), as well as blend miscibility, microstructure, mechanical properties, in vitro swelling behavior, and cell responses were studied.
PLA
-2K (molecular mass: 2096 g/mol) and
PLA
-63K (molecular mass: 63 000 g/mol) formed miscible and partially miscible blends with cross-linked PEGDMA, respectively. The addition of the
PLA
-2K did not affect the immediate or post-cure (>24 h) DC of the PEGDMA upon photopolymerization. However, the addition of
PLA
-63K decreased the immediate DC of the PEGDMA, which can be increased through extending the curing time or post-curing period. Compared to the cross-linked neat PEGDMA and
PLA
-2K/PEGDMA blends,
PLA
-63K/PEGDMA blends were significantly stronger, stiffer, and tougher. Both types of blends and the cross-linked PEGDMA swelled when soaked in a phosphate buffered saline (PBS) solution. The attachment and spreading of
MCT3
-E1 cells increased with increasing
PLA
-63K content in the blends. The facile and rapid formation of PEGDMA/
PLA
blends by photopolymerization represents a simple and efficient approach to a class of biomaterials with a broad spectrum of properties.
...
PMID:In situ formation of blends by photopolymerization of poly(ethylene glycol) dimethacrylate and polylactide. 1587 85